iPharma
iPharma is a Russia-based private CRO founded in 2012 within KhimRar Group, providing full-cycle clinical development, bioequivalence, post-marketing, and pharmacovigilance services to pharmaceutical and biotech sponsors across 25+ countries via proprietary EDC, randomization, and sponsor monitoring platforms.
- Company typePrivate
- Founded2012
- HeadquartersMoscow, Russia
- Headcount51–100
- GTM typeB2B
- OfferingServices
What iPharma does
iPharma is a private contract research organization (CRO) founded in 2012 and headquartered at the Skolkovo Innovation Center in Moscow. Operating under the legal entity LLC "Innovative Pharmaceuticals" (ООО «Инновационная Фармацевтика»), the company is a subsidiary within the KhimRar Group of Companies and delivers full-cycle clinical development services to pharmaceutical and biotech sponsors — from early-phase first-in-human studies through registration trials, bioequivalence, post-marketing programs, and pharmacovigilance.
The company's core technology stack centers on a suite of proprietary digital platforms: an Electronic Data Capture (EDC) system for clinical data management, the iRand randomization module, the Sponsor Cabinet real-time monitoring portal (integrated with EDC), and the ClinLine.ru and ClinMarket.ru marketplaces connecting sponsors, sites, vendors, researchers, and patients. This infrastructure is built to FDA 21 CFR Part 11 standards with Tier Level 4 data centers and 3-2-1 backup architecture, and supports operations across Russia, EAEU countries, Serbia, China, and Australia via an international partner network spanning 25+ countries.
iPharma generates revenue through professional services contracts on a quote-based pricing model, with free feasibility consultations offered via its website. Its GTM combines consultative enterprise sales targeting pharma and biotech sponsors of all sizes with channel-based distribution through international partners. The company has studied 340+ drugs, prepared 77+ for registration, registered 87+ medical devices, and conducted 310+ clinical studies, and has consistently ranked among AOKI leaders for Russian innovative drug trial volume from 2013-2023, including #1 rankings in 2017, 2018, and 2020.
iPharma firmographics
Firmographics- Name
- iPharma
- Legal name
- OOO «Инновационная Фармацевтика»
- Website
- https://ipharma.ru
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- iPharma is a Russia-based private CRO founded in 2012 within KhimRar Group, providing full-cycle clinical development, bioequivalence, post-marketing, and pharmacovigilance services to pharmaceutical and biotech sponsors across 25+ countries via proprietary EDC, randomization, and sponsor monitoring platforms.
- Ownership category
- akta.pro rank
iPharma industry classification
Industry- Product category
- Contract Research Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)
Keywords
Where iPharma is headquartered
LocationHeadquarters
- HQ city
- Moscow
- HQ country
- Russia
- HQ region
- Europe
Offices2 records
Markets served
iPharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services (CRO): iPharma operates as a contract research organization (CRO) providing full-cycle clinical development services from early phases to registration, including pharmacovigilance, data management, biostatistics, regulatory support, centralized monitoring, clinical monitoring, logistics, central laboratory services, and observational programs. Revenue is generated through professional services contracts with pharmaceutical and biotech companies.
- Post-marketing Programs and Observational Studies: The company conducts post-marketing surveillance programs and observational studies that provide additional revenue streams after drug registration.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
iPharma product offering
Product offeringCore offering
iPharma is a Contract Research Organization (CRO) that provides full-cycle clinical development services for pharmaceutical and biotechnology sponsors. Its core service portfolio covers early-phase clinical studies, registration (Phase II/III) clinical trials, bioequivalence studies, post-marketing programs, and pharmacovigilance, supported by proprietary EDC, randomization, sponsor-portal, and marketplace platforms.
Product overview
iPharma is a contract research organization (CRO) offering a unified platform approach to clinical trial management. The core EDC (Electronic Data Capture) system serves as the central platform, integrated with the Sponsor Office portal for real-time trial monitoring and the iRand randomization module. Supporting platforms include ClinLine.ru for patient/researcher engagement and ClinMarket.ru for marketplace functionality. The company provides comprehensive CRO services spanning clinical trial documentation development, quality assurance, regulatory support, data processing, clinical monitoring, centralized monitoring, pharmacovigilance, biomedical statistics, central laboratory coordination, observational programs, and logistics.
Differentiator
Problem solved
Functional benefit
Brands
- EDC: Electronic Data Capture system for collecting clinical study data
- iRand
- Kabinet Sponsora (Sponsor Cabinet)
- ClinMarket
- ClinLine
Products and services
- Clinical Trial Management Services Full-cycle management of clinical studies for pharmaceutical and biotechnology sponsors, covering early-phase trials, registration (Phase II/III) studies, bioequivalence trials, and post-marketing clinical programs, delivered from iPharma's Skolkovo base.
- Pharmacovigilance Services Ongoing safety surveillance and reporting service supporting pharmaceutical and biotech sponsors across their product lifecycle, including post-marketing safety oversight.
- Electronic Data Capture (EDC) Platform Proprietary Electronic Data Capture platform used to capture, manage, and quality-control clinical research data for sponsor studies.
- iRand Randomization Tool Proprietary randomization tool used by iPharma to assign subjects to treatment arms in clinical trials, supporting study integrity and protocol compliance.
- Sponsor Cabinet (Кабинет спонсора) Proprietary sponsor portal that gives pharmaceutical and biotech sponsors self-service access to study progress, documents, and data from iPharma-run clinical trials.
- ClinLine.ru Online portal that connects iPharma with medical and clinical specialists interested in participating in clinical research projects.
- ClinMarket.ru Online marketplace operated by iPharma that connects clinical research professionals and service providers with pharmaceutical sponsors and CROs.
Quantifiable outcome
- 77+ drugs prepared for registration
- +4 more outcomes
Companies that use iPharma
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
iPharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
iPharma partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- International Clinical Trial PartnerscoreExpanded partnership network enabling clinical trial conduct in more than 25 countries. First clinical trial launched in Australia in 2024 through international partnerships. Core services including data management and biostatistics are competitive internationally.
- First Moscow State Medical University named after I.M. SechenovminorAgreement on scientific cooperation signed in 2016 with the First Moscow State Medical University named after I.M. Sechenov. iPharma conducts seminars and educational programs with the university's Pharmaceutical Faculty's Industrial Pharmacy Department.
- Open University of Skolkovo (Pharma's cool)minoriPharma conducts seminars under the Pharma's cool educational program of the Open University of Skolkovo, providing training for clinical research professionals and students.
- KhimRar Group of Companies (ХимРар)coreiPharma is a CRO within the KhimRar Group of Companies (part of CVT KhimRar), one of the biopharmaceutical industry leaders in Russia. KhimRar's research platform extends iPharma's capabilities in chemical synthesis, drug product development and manufacturing, preclinical and bioanalytical studies, and financial instruments.
- Skolkovo TechnoparkcoreiPharma is a partner of Skolkovo Technopark. The company opened its office in Skolkovo in 2015. iPharma's iPharma Center for Collective Use is registered with Skolkovo. The company participates in Skolkovo's Pharma's cool educational programs and innovation projects.
- Doktoris (Доктис)minorDigital ecosystem in healthcare. Listed as a partner/ecosystem member in the KhimRar group network.
- SberbankminorListed as partner for implementing innovative projects of Russia's largest bank, suggesting involvement in institutional innovation and healthcare digitalization programs.
- MIPT (Moscow Institute of Physics and Technology)minoriPharma provides training for students at MIPT through the StudStock program and the 5th course of the Department of Innovative Pharmacy, Medical Equipment and Biotechnology on 'Biostatistics in Clinical Research'.
Scale indicators15 records
Recent moves10 records
Expansion highlights5 records
iPharma competitors and assessment
Company assessmentBroad incumbents
- Medpace Holdings: Mid-to-large global CRO focused on small/mid-biotech sponsors with full-service clinical development. Overlaps with iPharma's biotech-focused customer segment and end-to-end clinical trial model.
- Worldwide Clinical Trials: Mid-sized global CRO with strong scientific and therapeutic-area expertise. Comparable to iPharma in full-service clinical development and mid-cap sponsor focus.
- Charles River Laboratories: Global CRO/CDMO offering preclinical, clinical, and manufacturing services. Comparable to iPharma especially in clinical trial services and via the broader KhimRar Group integration across discovery-to-clinical.
- Syneos Health: Global clinical and commercial solutions provider. Comparable end-to-end CRO offerings to iPharma across clinical development, biometrics, and pharmacovigilance.
- ICON plc: Large global CRO with strong data management, biostatistics, and EDC capabilities following PRA Health Sciences merger. Directly comparable service portfolio to iPharma, with broader geographic reach and established sponsor relationships.
- Parexel International: Global full-service CRO with deep biotech and large-pharma clinical trial services. Comparable full-cycle offerings including Phase I-IV, biostatistics, regulatory, and pharmacovigilance — overlapping with iPharma's stack.
- IQVIA: Global #1 CRO with full-service clinical and RWE offerings. Comparable to iPharma across clinical trial management, data/biostatistics, and EDC-adjacent platforms; competes for the same multinational sponsors though iPharma has stronger Russia/EAEU localization.
Direct peers
- OCT Clinical: Russian CRO with full-service Phase I-IV clinical trial offerings across Eastern Europe. Most direct regional competitor to iPharma, also serving Russian and EAEU sponsors.
- Evidence Clinical Research: Russian CRO providing clinical trial management and regulatory services. Directly comparable to iPharma in Russia-domiciled full-service CRO offerings.
- Ergomed (now private, formerly PrimeVigilance/Syntegra): CRO with strong pharmacovigilance and clinical trial services for orphan/rare and specialty therapeutics. Comparable to iPharma in specialty therapeutic focus and PV outsourcing capabilities.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
iPharma social profiles
Digital presenceiPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
iPharma leadership team
Management profileNumber of profiles
Profiles1 record
iPharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iPharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iPharma
What does iPharma do?
iPharma is a Contract Research Organization (CRO) that provides full-cycle clinical development services for pharmaceutical and biotechnology sponsors. Its core service portfolio covers early-phase clinical studies, registration (Phase II/III) clinical trials, bioequivalence studies, post-marketing programs, and pharmacovigilance, supported by proprietary EDC, randomization, sponsor-portal, and marketplace platforms.
Is iPharma a public or private company?
iPharma is a private company. It is classified as corporate owned and is currently operating.
When was iPharma founded?
iPharma was founded in 2012. It employs 51 to 100 people.
Where is iPharma based?
iPharma is headquartered in Moscow, Russia, in the Europe region.
How does iPharma make money?
Two revenue lines are on record. Clinical Research Services (CRO) is the primary driver. The others are post-marketing Programs and Observational Studies.
Who are iPharma's main competitors?
Broad incumbents on record are Medpace Holdings, Worldwide Clinical Trials, Charles River Laboratories, Syneos Health, ICON plc, Parexel International and IQVIA. Direct peers are OCT Clinical, Evidence Clinical Research and Ergomed (now private, formerly PrimeVigilance/Syntegra).
Does iPharma have an API?
No public API is recorded for iPharma.
What industry is iPharma in?
iPharma's product category is Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGACAC, Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts). Its NAICS code is 5417 and its SIC code is 8731.